Literature DB >> 19962580

The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline.

Nadine Shehata1, Valerie A Palda, Ralph M Meyer, Tom D Blydt-Hansen, Patricia Campbell, Carl Cardella, Steven Martin, Peter Nickerson, Kevork Peltekian, Heather Ross, Tom K Waddell, Lori West, David Anderson, John Freedman, Heather Hume.   

Abstract

This guideline for the use of immunoglobulin (IG) for sensitized patients undergoing solid organ transplantation (SOT) is an initiative of the Canadian Blood Services and the National Advisory Committee on Blood and Blood Products of Canada to (1) provide guidance for Canadian practitioners involved in the care of patients undergoing SOT and transfusion medicine specialists on the use of IG and (2) standardize care, limit adverse events, and optimize patient care. A systematic expert and bibliography literature search up to July 2008 was conducted, with 791 literature citations and 45 reports reviewed. To validate the recommendations, the guideline was sent to physicians involved in SOT in Canada and a patient representative. The recommendations identify (1) sensitized patients undergoing SOT that would have a better survival and decreased morbidity by receiving IG preoperatively, postoperatively, and for the treatment of organ rejection; (2) patients who may not have any benefit from receiving IG; and (3) potential adversities to IG.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19962580     DOI: 10.1016/j.tmrv.2009.09.010

Source DB:  PubMed          Journal:  Transfus Med Rev        ISSN: 0887-7963


  21 in total

Review 1.  Immunosuppression and allograft rejection following lung transplantation: evidence to date.

Authors:  Gregory I Snell; Glen P Westall; Miranda A Paraskeva
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Privigen immune globulin intravenous (human), 10% liquid.

Authors: 
Journal:  P T       Date:  2011-08

3.  Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy.

Authors:  A A Vo; S C Jordan
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Multispecialty Rating of Evidence-Based Conditions for Intravenous Immunoglobulin Therapy Using a 3-Axis Prioritization Algorithm.

Authors:  Jordan S Orange; Matt Johnson; Barb Lennert; Katarzyna Shields; Michael Eaddy
Journal:  Am Health Drug Benefits       Date:  2017-05

5.  Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases.

Authors:  Gisele Zandman-Goddard; Alexander Krauthammer; Yair Levy; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

6.  Advances in the treatment of pulmonary tuberculosis.

Authors:  Xia Zhang; Jing Guo
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

Review 7.  Targeting B cells and antibody in transplantation.

Authors:  M R Clatworthy
Journal:  Am J Transplant       Date:  2011-06-10       Impact factor: 8.086

8.  Incompatible live-donor kidney transplantation in the United States: results of a national survey.

Authors:  Jacqueline M Garonzik Wang; Robert A Montgomery; Lauren M Kucirka; Jonathan C Berger; Daniel S Warren; Dorry L Segev
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

9.  Induction Therapy and Therapeutic Antibodies.

Authors:  Andriana Nikolova; Jignesh K Patel
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.